Core Insights - Nasus Pharma Ltd. is set to host a conference call and webcast on March 16, 2026, to present the topline analysis from the Phase 2 repeated dose clinical study of NS002, an intranasal powder epinephrine product candidate [1] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal powder products for acute medical conditions [4] - The NS002 product is being developed as a needle-free alternative to epinephrine autoinjectors for patients experiencing anaphylaxis [4] - The company's proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [4] - The PBI formulation employs uniform spherical powder particles for broad dispersion and potentially faster absorption compared to liquid-based nasal products [4] Conference Call Details - The conference call will take place at 8:00 a.m. ET on March 16, 2026, and will include a question-and-answer session following the data presentation [1] - Individuals can register for the webcast through a provided link, and dial-in numbers for the conference call are available for both US and international participants [6]

Core Viewpoint - Nasus Pharma Ltd. is participating in the upcoming virtual Life Sciences Investor Forum, showcasing its innovative intranasal products aimed at treating emergency medical conditions [1]. Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute medical conditions [3]. - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine, designed as a needle-free alternative to traditional autoinjectors for anaphylaxis treatment [3]. - The proprietary powder-based intranasal (PBI) technology enables rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [3]. - The PBI formulation features uniform spherical powder particles, which may allow for broader dispersion and potentially faster absorption compared to liquid-based nasal products [3]. Presentation Details - Company management will be available for one-on-one meetings during the conference, and interested parties are encouraged to arrange meetings through their conference representative [2]. - The presentation is scheduled for March 11, 2026, at 12:30 p.m. ET, and will be led by CEO Dan Teleman [4].

Core Viewpoint - Nasus Pharma Ltd. has successfully closed a private placement of ordinary shares and warrants, raising approximately $15.0 million to advance its clinical development programs, particularly the NS002 intranasal epinephrine product candidate [1][3]. Group 1: Private Placement Details - The private placement involved the sale of 2,695,425 ordinary shares and accompanying warrants at a combined purchase price of $5.565 per share [3][5]. - Citizens Capital Markets acted as the lead placement agent, with Laidlaw & Company (UK) Ltd. serving as the co-placement agent [2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized to advance the pivotal clinical development of NS002 for anaphylaxis treatment, initiate first-in-human studies for other products, and for general corporate purposes [5]. Group 3: Product Development Focus - NS002 is being developed as a needle-free alternative to epinephrine autoinjectors, aimed at providing rapid drug delivery in emergency situations [8]. - The company is focused on leveraging its proprietary intranasal technology across various therapeutic areas to enhance clinical value [3][8]. Group 4: Financial Strengthening - The financing is expected to significantly strengthen the company's balance sheet and provide funding visibility for planned operations and development activities [3][5]. Group 5: Warrants Information - The warrants have an exercise price of $6.53 per share, are immediately exercisable, and will expire two years from issuance or 30 trading days after the announcement of NS002 pivotal study results [4].